Eshallgo Inc. Announced Receipt of Notice from Nasdaq regarding Listing Rule 5550(a)(2).

(NASDAQ:EHGO), New York, July 25, 2025 (GLOBE NEWSWIRE) — Shanghai, China July 25, 2025 – Eshallgo, Inc. (NASDAQ:EHGO) (“Eshallgo” or the “Company”) today announced that on July 23, 2025, the Company received a notice from the staff of the Nasdaq Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for […]

ECN Capital Schedules Q2-2025 Conference Call

ECN Capital Schedules Q2-2025 Conference Call GlobeNewswire July 25, 2025 TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — ECN Capital Corp. (TSX: ECN) (“ECN Capital” or “the Company”) announced today that it intends to file its financial statements and management discussion and analysis for the three-month period ended June 30, 2025, after markets close on Thursday,

Eshallgo Inc. Announced Receipt of Notice from Nasdaq regarding Listing Rule 5550(a)(2).

Eshallgo Inc. Announced Receipt of Notice from Nasdaq regarding Listing Rule 5550(a)(2). GlobeNewswire July 25, 2025 New York, July 25, 2025 (GLOBE NEWSWIRE) — Shanghai, China July 25, 2025 – Eshallgo, Inc. (NASDAQ:EHGO) (“Eshallgo” or the “Company”) today announced that on July 23, 2025, the Company received a notice from the staff of the Nasdaq

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT GlobeNewswire July 25, 2025 NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September

FISERV, INC. (NYSE: FI) INVESTOR ALERT Investors With Large Losses in Fiserv, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Fiserv, Inc. ("Fiserv" or the "Company") (NYSE:FI) between July 24, 2024 and July 22, 2025,

Barnes & Noble Education, Inc. Investors: Company Investigated by the Portnoy Law Firm

(NYSE:BNED), Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Barnes & Noble Education, Inc. (“Barnes & Noble” or “the Company”) (NYSE: BNED) investors that the firm has initiated an investigation into possible securities fraud

Barnes & Noble Education, Inc. Investors: Company Investigated by the Portnoy Law Firm

Barnes & Noble Education, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire July 25, 2025 Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Barnes & Noble Education, Inc. (“Barnes & Noble” or

DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of The McKenzie Memorial Hospital Customers Whose Data May Have Been Compromised

The law firm ofEdelson Lechtzin LLP, in suburban Philadelphia, is investigating data privacy claims regarding an incident at McKenzie Memorial Hospital. McKenzie Memorial Hospital learned of a data breach on or about June 19, 2025. https://mma.prnewswire.com/media/2457789/logo2_Logo.jpg If you would like to discuss this case with a lawyer, please click HERE. About McKenzie Memorial Hospital McKenzie

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ:REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

NEW YORK CITY, NY / ACCESS Newswire / July 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ:TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Telix and certain of its officers and/or

Scroll to Top